NABI pharm. suffered a devestating setback when their lead product StaphVax for controlling staph infection failed phase 3. Company has since figured out the problem the first 2 test phases they produced their own antibodies and the 3rd they used the manufacturing facility that they were going to use to ship to europe. Huge mmistake by mangement! Those antibodies weren't as pure, also there was some problem with the type of patients (kidney infection & such). What are we left with? A small Bio with 3 small products already on the market with sales of $50 million and they just bought the rights to a transplant rejection drug for marketing. A pipeline candidate for stopping smokeing NicVax which looks very promising and an earnings report this upcoming wed. Might management take the opportunity to paint a pretty picture about StaphVax's potential comback?... Spec Buy.